Form 4: BioLife Solutions Director Receives Equity Grant

Catherine Coste, a Director at BioLife Solutions Inc., was granted 8,170 shares of common stock as part of the company's 2023 Performance Incentive Plan.

Summary

• Director Catherine Coste of BioLife Solutions Inc. (BLFS) acquired 8,170 shares of common stock.
• The transaction occurred on February 24, 2026.
• Following this transaction, Catherine Coste beneficially owns a total of 13,871 shares of common stock.
• The shares were granted under the BioLife Solutions 2023 Performance Incentive Plan.
• The restricted stock fully vests on the first anniversary of the vesting date of January 2, 2026, meaning it vests on January 2, 2027.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating continued insider confidence and alignment of a director's interests with the company's long-term performance through equity compensation.

Positives

• Increased insider ownership by a Director, signaling alignment with shareholder interests.
• The grant is part of a performance incentive plan, linking executive compensation to company performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are a standard practice in the biotechnology and life sciences industry, aligning management incentives with long-term company performance and shareholder value creation. This particular grant is consistent with typical compensation structures for board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Potentially positive, as increased insider ownership can signal confidence and align director interests with shareholder returns.
• Employees: The grant is part of an incentive plan, which generally supports a performance-driven culture.

Next Steps

• The restricted stock grant will fully vest on January 2, 2027.

Key Dates

Keywords

BioLife Solutions, BLFS, Insider Transaction, Form 4, Equity Grant, Restricted Stock, Director Compensation, Performance Incentive Plan